Last $172.43 USD
Change Today +2.00 / 1.17%
Volume 1.7M
AGN On Other Exchanges
Symbol
Exchange
Berlin
As of 8:04 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$169.22
Previous Close
$170.43
Day High
$173.00
Day Low
$169.05
52 Week High
06/30/14 - $174.49
52 Week Low
09/11/13 - $86.95
Market Cap
51.2B
Average Volume 10 Days
1.8M
EPS TTM
$5.14
Shares Outstanding
296.8M
EX-Date
08/13/14
P/E TM
33.6x
Dividend
$0.20
Dividend Yield
0.12%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. The company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,400 Employees
Last Reported Date: 02/25/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $651.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $641.5K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Valeant it has Filed a Complaint with Securities Regulators in Quebec and the U.S

Valeant said on July 21, 2014 it has filed a complaint with securities regulators in Quebec and the U.S. over allegedly unfair tactics by Allergan Inc. Valeant said it has contacted both the Autorité des marchés financiers and the U.S. Securities and Exchange Commission regarding Allergan's "apparent attempt to mislead investors and manipulate the market for Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information. Valeant says Allergan falsely stated last Friday in an SEC filing that Valeant's Bausch + Lomb pharmaceutical sales were stagnant or declining, when in fact they grew about 6% in the second quarter. The U.S. prescription pharmaceutical business grew 17% over the year-earlier period, with the lion's share of that growth due to volume increases.

Allergan Inc. to Cut Jobs

Allergan Inc. announced that they will cut 1,500 jobs, or 13% of their workforce, and take a pretax charge of $375 million to $425 million for severance and other costs related to a restructuring. Allergan also said it will eliminate an additional 250 vacant jobs as part of a sweeping cost-cutting and efficiency-boosting initiative it says will deliver annual pre-tax savings of about $475-million in calendar 2015.

Allergan Inc. Declares Dividend for Second Quarter of 2014, Payable on September 5, 2014

Allergan Inc. announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 5, 2014 to stockholders of record on August 15, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $172.43 USD +2.00

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $219.63 USD +3.26
Astellas Pharma Inc ¥1,409 JPY -2.50
Beiersdorf AG €67.81 EUR +0.51
Mylan Inc/PA $52.34 USD +0.28
Shire PLC 4,977 GBp +22.00
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 39.0x
Price/Sales 7.5x
Price/Book 7.5x
Price/Cash Flow 36.1x
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.